Biotechnology company Aicuris Anti-Infective Cures AG has announced its Phase III trial of pritelivir, a treatment for Herpes Simplex Virus (HSV), has reached its primary endpoint. 

The first-in-class helicase primase inhibitor met its primary endpoint of superiority (p=0.0047) in lesion healing in HSV patients receiving treatment up to 28 days. Statistical superiority in lesion healing further increased in patients receiving up to 42 days of treatment (p<0.0001). 

Pritelivir is a small-molecule antiviral targeting the helicase-primase complex of HSV. The candidate’s novel mechanism of action does not rely on activation by viral enzymes, allowing it to overcome HSV infections that are R±R to treatments, such as acyclovir, valacyclovir, famciclovir and foscarnet. 

The aim of the Phase III trial was to evaluate the efficacy and safety of pritelivir compared to SoC (investigator’s choice of foscarnet, cidofovir, compounded topical cidofovir or imiquimod) in treating immunocompromised patients with refractory HSV infection, with or without resistance (R±R). 

“As a clinician who treats immunocompromised patients and understands how HSV infections disrupt their lives, I view this Phase III as a significant step forward,” said Genovefa Papanicolaou, Clinical Director of Infectious Disease Service at Memorial Sloan Kettering Cancer Center and Professor at Weill Cornell College of Medicine. “There has been no HSV treatment innovation for this patient group for decades and pritelivir has the potential to be life-changing in particular for R±R patients where an orally available and safe option could significantly improve quality of life.” 

‘Major milestone’ for HSV treatments

Herpes Simplex Virus (HSV) includes two types, HSV-1 and HSV-2, both of which cause lifelong infections. HSV-1 typically leads to labial herpes, typically resulting in cold sores, while HSV-2 is commonly associated with genital herpes. These viruses can cause recurrent painful lesions and sores and, in severe cases, complications such as encephalitis, meningitis, disseminated disease, keratitis and neonatal herpes. 

HSV infections are widespread globally, with a significant impact on public health. According to the World Health Organization, an estimated 3.8 billion people under the age of 50, or 64% of the global population, were infected with HSV-1 in 2020. In that same year, 520 million people aged 15 to 49 were living with genital herpes caused by HSV-2. 

Immunocompromised patients are particularly prone to more severe, prolonged and refractory HSV infections that are difficult to treat and do not respond to standard-of-care (SoC). These infection outbreaks can cause painful lesions, drastically reducing quality of life, increasing the risk of hospitalisation and disseminated infection. Several SoC treatments require intravenous infusions and are poorly tolerated, with common side effects including kidney toxicity and electrolyte imbalances with risk of seizures requiring in-patient hospital management. 

“We plan to rapidly advance our New Drug Application submission to the FDA, and we look forward to presenting a comprehensive analysis of these positive results at a medical conference next year,” added Larry Edwards, CEO of Aicuris. “This major milestone underscores our commitment to developing innovative therapies focused on improving the lives of immunocompromised patients.” 

 

Bruno Quinney, Content Team, DDW